General information about company								
Name of The Company	SUVEN PHARMACEUTICALS LIMITED							
BSE Scrip Code	543064							
NSE Symbol	SUVENPHAR							
MSE Symbol	NA							
Date of Start of Financial Year	01-04-2024							
Date of End of Financial Year	31-03-2025							
Reporting Period	First half yearly							
Date of Start of Reporting Period	01-04-2024							
Date of End of Reporting Period	30-09-2024							
Level of rounding to be used in disclosing related party transactions	Crores							
Whether the company has any related party?	Yes							
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes							

(I) We declare that the acceptance of fixed deposits by the bans/Non- Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	08-02-2022
Indicate Company website link for updated RPT policy of the Company	https://www.suvenpharm.com/images/pdf/policies/Policy_on_Related_Party_Transactions_2022.pdf

								Related	party tra	insactions												
													relat	es to loans, in	ter-co	rporate d	transactions - leposits, advan to be disclosed transaction wa	only one	estment e, durin	s made or g	iven by the	listed
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty					Value of			In case monies are due to either party as a result of the transaction		incurred to make or give loans, inter- t corporate deposits, advances or				3				eposits,	
Sr No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period		Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness		Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	Suven Pharmaceuticals Limited	ABBCS1159F	Cohance lifesciences limited		Common Promoter	Any other transaction	Lease Rental income	0.09	NA	0.05	0	0										Textual Information(1
2	Suven Pharmaceuticals Limited	ABBCS1159F	Cohance lifesciences limited		Common Promoter	Sale of goods or services		10	NA	0.77	0	0										Textual Information(2
3	Suven Pharmaceuticals Limited	ABBCS1159F	Cohance lifesciences limited		Common Promoter	Any other transaction	Consultancy charges income	0.23	NA	0.06	0	0										Textual Information(3)
4	Suven Pharmaceuticals Limited	ABBCS1159F	Casper pharma private limited		Wholly Owned Subsidiary	Any other transaction	Lease Rental income	0	NA	0.02	0	0										Textual Information(4
5	Suven Pharmaceuticals Limited	ABBCS1159F	Casper pharma private limited		Wholly Owned Subsidiary	Sale of goods or services		0	NA	0.67	0	0										Textual Information(5)
6	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Vivek Sharma(w.e.f September 20, 2024)		Key management personnel	Remuneration		0	NA	1.36	0	0										Textual Information(6
7	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Annaswamy Vaidheesh (till September 19, 2024)		Key management personnel	Remuneration		0	NA	2.98	0	0										Textual Information(7
8	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Sudhir Kumar Singh		Key management personnel	Remuneration		0	NA	2.31	0	0										Textual Information(8
9	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Himanshu Agarwal		Key management personnel	Remuneration		0	NA	2.06	0	0										Textual Information(9)
10	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Kundan Kumar Jha		Key management personnel	Remuneration		0	NA	0.1	0	0										Textual Information(1
11	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Vinod Rao		Key management personnel	Any other transaction	Independent director fee	0.3	NA	0.15	0	0										Textual Information(1
12	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Kumarapuram Gopalakrishnan Ananthakrishnan		Key management personnel	Any other transaction	Independent director fee	0.3	NA	0.15	0	0										Textual Information(12
13	Suven Pharmaceuticals Limited	ABBCS1159F	Mrs.Matangi Gowrishankar		Key management personnel	Any other transaction	Independent director fee	0.3	NA	0.15	0	0										Textual Information(1
14	Suven Pharmaceuticals Limited	ABBCS1159F	Mr.Pravin Udhyavara Bhadya Rao		Key management personnel	Any other transaction	Independent director fee	0.3	NA	0.15	0	0										Textual Information(1
15	Sapala Organics Private Limited	AAJCS1655F	Dr. Paidi Yella Reddy (Director)		personnel	Remuneration		0	NA	0.37	0	0										Textual Information(1
16	Sapala Organics Private Limited	AAJCS1655F	Sampada Laboratories Pvt Ltd		Enterprise over which KMP have significant influence	Any other transaction	House keeping and Security services	0	NA	0.32	0	0										Textual Information(1
17	Sapala Organics Private Limited	AAJCS1655F	Sampada Laboratories Pvt Ltd		Enterprise over which KMP have significant influence	Any other transaction	Travelling expenses	0	NA	0.01	0	0										Textual Information(1
18	Sapala Organics Private Limited	AAJCS1655F	Sampada Laboratories Pvt Ltd		Enterprise over which KMP have significant influence	Any other transaction	Reimbursement of Gratuity	0	NA	0.01	0	0										Textual Information(1
19	Sapala Organics Private Limited	AAJCS1655F	Rasayan Inc		Shareholder	Purchase of goods or services		0	NA	0.38	0	0										Textual Information(1
20	Sapala Organics Private Limited	AAJCS1655F	Sapala Co Ltd, Japan		Enterprise over which KMP have significant influence	Sale of goods or services		0	NA	1.82	0	0										Textual Information(2
21	Sapala Organics Private Limited	AAJCS1655F	Sapala Co Ltd, Japan		Enterprise over which KMP have significant influence	Purchase of goods or services		0	NA	0.07	0	0										Textual Information(2
22	Casper Pharma Private Limited	AAGCC3439C	Cohance lifesciences limited		Common Promoter	Any other transaction	Rental expense	0	NA	0.05	0	0										Textual Information(2
23	Casper Pharma Private Limited	AAGCC3439C	Rohit Kumar Agarwal		Key management personnel	Remuneration		0	NA	0.07	0	0										Textual Information(2
24	Sapala Organics Private Limited	AAJCS1655F	Cohance lifesciences limited		Fellow subsidiary with effect from July 12, 2024	Any other transaction	Consultancy charges expense	0	NA	0.06	0	0										Textual Information(2
Total value of transaction during the reporting period										14.14												

Text Block							
Textual Information(1)							
Textual Information(2)							
Textual Information(3)							
Textual Information(4)							
Textual Information(5)							
Textual Information(6)							
Textual Information(7)							
Textual Information(8)							
Textual Information(9)	inculdes advance of 0.75 crores						
Textual Information(10)							
Textual Information(11)							
Textual Information(12)							
Textual Information(13)							
Textual Information(14)							
Textual Information(15)							
Textual Information(16)							
Textual Information(17)							
Textual Information(18)							
Textual Information(19)							
Textual Information(20)							
Textual Information(21)							
Textual Information(22)							
Textual Information(23)							
Textual Information(24)							